Status:
UNKNOWN
Immune Checkpoint Inhibitor Therapy- Induced Endocrinopathy
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Endocrinopathy
Eligibility:
All Genders
20-85 years
Brief Summary
To review cases from NTUH who developed endocrinopathy and metabolic diseases after immunotherapy, and statistically analyzed their age, clinical presentation, image findings, treatment and its respon...
Detailed Description
Immune checkpoint blockade-based immunotherapy is a new modality of cancer treatment with a unique mechanism that has gained increased numbers of indication and is now used in several cancer types. Ho...
Eligibility Criteria
Inclusion
- Patients who receive immunotherapy in NTUH and develop endocrinopathy after therapy
Exclusion
- Patients less than 20 years old. Patients who are pregnant
Key Trial Info
Start Date :
July 3 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04079647
Start Date
July 3 2018
End Date
July 1 2025
Last Update
September 6 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shyang-Rong Shih
Taipei, Taiwan